Leerink Partnrs Has Weak Outlook for DexCom FY2025 Earnings

DexCom, Inc. (NASDAQ:DXCM) – Equities researchers at Leerink Partnrs lowered their FY2025 earnings estimates for DexCom in a report issued on Monday, November 25th. Leerink Partnrs analyst M. Kratky now forecasts that the medical device company will post earnings per share of $2.06 for the year, down from their prior forecast of $2.07. The consensus estimate for DexCom’s current full-year earnings is $1.71 per share. Leerink Partnrs also issued estimates for DexCom’s Q4 2025 earnings at $0.66 EPS.

Other research analysts have also recently issued reports about the stock. StockNews.com cut shares of DexCom from a “buy” rating to a “hold” rating in a report on Saturday, November 2nd. Oppenheimer lowered their price objective on shares of DexCom from $115.00 to $105.00 and set an “outperform” rating on the stock in a research report on Friday, October 25th. Sanford C. Bernstein boosted their target price on shares of DexCom from $82.00 to $86.00 and gave the company an “outperform” rating in a research note on Friday, October 25th. JPMorgan Chase & Co. raised their target price on DexCom from $75.00 to $85.00 and gave the stock a “neutral” rating in a research report on Friday, October 25th. Finally, Royal Bank of Canada dropped their price target on DexCom from $120.00 to $115.00 and set an “outperform” rating on the stock in a research report on Friday, October 25th. Seven research analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $104.59.

DexCom Stock Performance

DXCM opened at $77.94 on Wednesday. The business has a fifty day simple moving average of $70.94 and a 200-day simple moving average of $88.58. The firm has a market cap of $30.44 billion, a PE ratio of 46.67, a P/E/G ratio of 2.38 and a beta of 1.17. DexCom has a fifty-two week low of $62.34 and a fifty-two week high of $142.00. The company has a quick ratio of 2.12, a current ratio of 2.46 and a debt-to-equity ratio of 1.23.

Insider Activity at DexCom

In related news, EVP Sadie Stern sold 4,259 shares of the firm’s stock in a transaction that occurred on Wednesday, November 20th. The stock was sold at an average price of $74.73, for a total value of $318,275.07. Following the transaction, the executive vice president now directly owns 71,192 shares of the company’s stock, valued at approximately $5,320,178.16. This trade represents a 5.64 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, COO Jacob Steven Leach sold 746 shares of the business’s stock in a transaction that occurred on Monday, September 9th. The stock was sold at an average price of $69.15, for a total value of $51,585.90. Following the completion of the sale, the chief operating officer now owns 264,915 shares of the company’s stock, valued at approximately $18,318,872.25. This trade represents a 0.28 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 5,431 shares of company stock valued at $399,319. Insiders own 0.30% of the company’s stock.

Hedge Funds Weigh In On DexCom

A number of institutional investors have recently made changes to their positions in the business. Capital Insight Partners LLC raised its stake in DexCom by 2.5% during the 2nd quarter. Capital Insight Partners LLC now owns 3,690 shares of the medical device company’s stock valued at $418,000 after purchasing an additional 90 shares during the last quarter. HM Payson & Co. raised its position in shares of DexCom by 6.0% during the first quarter. HM Payson & Co. now owns 1,780 shares of the medical device company’s stock valued at $247,000 after buying an additional 100 shares during the last quarter. Clear Creek Financial Management LLC lifted its stake in shares of DexCom by 4.2% in the second quarter. Clear Creek Financial Management LLC now owns 2,961 shares of the medical device company’s stock valued at $336,000 after buying an additional 120 shares during the period. SeaCrest Wealth Management LLC grew its position in DexCom by 3.6% during the second quarter. SeaCrest Wealth Management LLC now owns 4,421 shares of the medical device company’s stock worth $501,000 after buying an additional 152 shares in the last quarter. Finally, Securian Asset Management Inc. increased its stake in DexCom by 0.7% during the second quarter. Securian Asset Management Inc. now owns 22,866 shares of the medical device company’s stock valued at $2,593,000 after acquiring an additional 161 shares during the period. 97.75% of the stock is currently owned by institutional investors.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.